Eli Lilly plans to spend at least $27bn to build four new manufacturing plants in the United States, the drugmaker has said as it grapples with the threat of drug import duties from the Trump administration.

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in pharmaceutical production.

After announcing plans to build four manufacturing sites in the U.S. on Wednesday, Eli Lilly chief executive officer Dave Ricks skillfully demurred when asked if the move might forestall tariffs that President Trump has threatened to levy on the pharmaceutical industry.

Eli Lilly and Company said Wednesday they plan to build new pharmaceutical manufacturing sites in the United States.

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry to reshore drug production.

Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 construction workers.

The story has been updated to correct the new site locations At a press conference in Washington, D.C., Eli Lilly And Co (NYSE:LLY) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States.

Eli Lilly and Company LLY announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (“CHMP”) has given a positive opinion recommending approval of its BTK inhibitor,

One of the worst flu seasons in years has reached its peak and is improving, officials with the Centers for Disease Control and Prevention announced Friday.